Why the study?
Bioprosthetic valve thrombosis is increasingly recognized after valve-in-valve procedures, but the best thromboprophylaxis regimen and optimal acute management strategy remain unknown.
Does thrombolysis successfully manage early thrombosis following percutaneous tricuspid valve-in-valve implantation?
Does thrombolysis successfully manage early thrombosis following percutaneous tricuspid valve-in-valve implantation?
Thrombolysis can be a successful management strategy for early bioprosthetic valve thrombosis following percutaneous tricuspid valve-in-valve implantation.
May support thrombolysis for early post-tricuspid valve-in-valve thrombosis; hypothesis-generating case report requiring prospective confirmation.
Bioprosthetic valve thrombosis (BPVT) is a growing recognized entity, especially with the increasing use of the valve in vale procedures and the advent of new detection technologies (e.g., 4D CT and 4D echocardiography). The incidence of BPVT is higher in transcatheter valves than surgically implanted bioprosthetic valves. However, the best thromboprophylaxis regimen and optimal management strategy in the acute context remain unknown. This paper presents a case of early thrombosis following the percutaneous tricuspid valve in vale procedure that was successfully managed with thrombolysis.
No takes yet. Share an insight, caveat, or question.
Shojaeifard et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: